Report cover image

Bacterial Vaginosis Drug Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Prescription Drugs and Over-the-Counter Drugs), Route of Administration (Oral, Topical, and Vagina

Publisher The Insight Partners
Published Feb 03, 2025
Length 184 Pages
SKU # TIP19655510

Description

According to our new research study on “Bacterial Vaginosis Drug Market Forecast to 2031 –Global Analysis – by Type, Route of Administration, Dosage Form, and Distribution Channel, and Geography,” the market is anticipated to grow from US$ 2.15 billion in 2024 and is projected to reach US$ 3.82 billion by 2031; it is expected to register a CAGR of 8.3% during 2024–2031. Rising prevalence of bacterial vaginosis, and the increased focus on developing novel and targeted therapies are contributing to the growing Bacterial Vaginosis Drug market size. However, the high recurrence rate and treatment adherence challenges hampers the Bacterial Vaginosis Drug market growth. Further, rising inclination toward microbiome therapies and probiotics are expected to bring in new Bacterial Vaginosis Drug market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for bacterial vaginosis drugs in the world. In the US, the bacterial vaginosis drug market is experiencing significant growth due to the increasing prevalence of BV, rising awareness about women's health, and ongoing efforts for the development of innovative treatments. BV is one of the most common vaginal infections in women, particularly affecting those of reproductive age. According to a report by Medscape in 2024, approximately one-third of adult women in the US, i.e., ~22 million females, are affected by BV annually, and 10 million women visit clinics for abnormal vaginal discharge. It is often linked to factors such as sexual activity, douching, and hormonal changes; nonetheless, there is uncertainty around the exact causes of BV. The primary therapeutic options available for treating BV include antibiotics approved by the US Food and Drug Administration (FDA), such as metronidazole and clindamycin. Metronidazole, often available in oral and topical forms, is considered the first-line treatment for BV. Clindamycin is also commonly available in both oral and topical formulations. Newer drugs and formulations, such as probiotics and phage therapy, are also emerging to help restore the natural vaginal flora, thereby reducing the recurrence of BV.

Government initiatives in the US play a key role in creating and spreading awareness about vaginosis in the population. The National Institutes of Health (NIH) funds research into the causes, treatment, and prevention of BV. The NIH's efforts have led to a deeper understanding of the microbiome and its role in causing BV, which is crucial for developing more targeted therapies. Centers for Disease Control and Prevention (CDC) provide guidelines and recommendations to improve the diagnosis and management of BV. These initiatives help standardize care and ensure that patients receive the most effective treatment. Additionally, the National Institute of Child Health and Human Development (NICHD, a federal agency) and NIH are dedicated to understanding BV and educating women about its causes and prevention. NICHD funds and conducts research on the risks associated with BV and methods for its prevention and treatment.

Bacterial Vaginosis Drug Market Analysis

Strategic Initiatives by Market Players to Provide Market Opportunities in Future

Companies operating in the bacterial vaginosis drugs market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and reinforce their capacities to cater to a greater than existing customer base. A few strategic initiatives by key players operating in the bacterial vaginosis drugs market are mentioned below.

In November 2024, Freya Biosciences received US$ 10.4 million in strategic investment from the Bill & Melinda Gates Foundation, with US$ 1.4 million in additional financing from the current investor—Export and Investment Fund of Denmark (EIFO). The company plans to use these funds to develop microbial immunotherapies for the treatment of BV to address the risk of preterm birth along with other indications potentially affecting maternal and newborn health.
In March 2022, Organon and Daré Bioscience, Inc. entered into an agreement whereby Organon will license global rights to XACIATO (clindamycin phosphate vaginal gel, 2%). With this, XACIATO received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US Food and Drug Administration (FDA) for the treatment of bacterial vaginosis.
In February 2022, Lupin Pharmaceuticals Inc. received FDA approval for a supplemental New Drug Application (sNDA) to increase the use of SOLOSEC (secnidazole) for the treatment of BV among female patients aged 12 or older; the approval also entailed the treatment of trichomoniasis among patients from the said age group.
In December 2021, the FDA approved XACIATO (clindamycin phosphate vaginal gel, 2%) manufactured by Daré Bioscience, Inc. for the treatment of bacterial vaginosis in females of age 12 years or more.
In February 2021, Rebiotix (Ferring) and MyBiotics collaborated to develop live microbiome-based therapeutics for applications in reproductive medicine and maternal health. This collaboration aims to create live microbiota-based biotherapeutics for bacterial vaginosis among women of childbearing age, which may be associated with the increased risk of miscarriage and complications in pregnancy and fertility.

Therefore, ongoing funding, product launches and approvals, and collaborations are expected to create ample opportunities for the growth of the bacterial vaginosis drugs market in the coming years.

Bacterial Vaginosis Drug Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Bacterial Vaginosis Drug market analysis are type, route of administration, dosage form, and distribution channel.

Based on type, the bacterial vaginosis drug market is segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment held a larger share of the market in 2024.
In terms of route of administration, the bacterial vaginosis drug market is categorized into oral, vaginal, and topical. The oral segment dominated the market in 2024.
In terms of dosage form, the bacterial vaginosis drug market is categorized into pills, creams, gels, solutions/washes, and others. The pills segment dominated the market in 2024.
In terms of distribution channel, the bacterial vaginosis drug market is categorized into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.

Bacterial Vaginosis Drug Market: Competitive Landscape and Key Developments

Bayer AG, Pfizer Inc, Sanofi SA, Starpharma Holdings Limited, Viatris Inc, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Sun Pharmaceutical Industries Ltd, Organon & Co, Duchesnay Inc., Canada are among the key companies operating in the Bacterial Vaginosis Drug market.

European Journal of Obstetrics & Gynecology and Reproductive Biology, National Institutes of Health, Medscape, Government of Canada, UN World Population Prospects 2024, Eurostat, European Commission, Australian Government’s Department of Health and Aged Care, World Bank, and International Trade Administration are among the primary and secondary sources referred to while preparing the Bacterial Vaginosis Drug market report.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the bacterial vaginosis drug market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the bacterial vaginosis drug market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the   market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table of Contents

184 Pages
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. Bacterial Vaginosis Drug Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Incidence Rate: Bacterial Vaginosis
5. Bacterial Vaginosis Drug Market – Key Market Dynamics
5.1 Bacterial Vaginosis Drug Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Prevalence of Bacterial Vaginosis
5.2.2 Increased Focus on Developing Novel and Targeted Therapies
5.3 Market Restraints
5.3.1 High Recurrence Rate and Treatment Adherence Challenges
5.4 Market Opportunities
5.4.1 Strategic Initiatives by Market Players
5.5 Future Trends
5.5.1 Rising Inclination Toward Microbiome Therapies and Probiotics
5.6 Impact of Drivers and Restraints:
6. Bacterial Vaginosis Drug Market – Global Market Analysis
6.1 Bacterial Vaginosis Drug Market Revenue (US$ Million), 2021–2031
6.2 Bacterial Vaginosis Drug Market Forecast Analysis
7. Bacterial Vaginosis Drug Market Analysis – by Type
7.1 Prescription Drugs (Rx)
7.1.1 Overview
7.1.2 Prescription Drugs (Rx): Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Over-the-counter Drugs (OTC)
7.2.1 Overview
7.2.2 Over-the-counter Drugs (OTC): Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
8. Bacterial Vaginosis Drug Market Analysis – by Route of Administration
8.1 Oral
8.1.1 Overview
8.1.2 Oral: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Vaginal
8.2.1 Overview
8.2.2 Vaginal: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Topical
8.3.1 Overview
8.3.2 Topical: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
9. Bacterial Vaginosis Drug Market Analysis – by Dosage Form
9.1 Pills
9.1.1 Overview
9.1.2 Pills: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Creams
9.2.1 Overview
9.2.2 Creams: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Gel
9.3.1 Overview
9.3.2 Gel: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Solution or Washes
9.4.1 Overview
9.4.2 Solution or Washes: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
10. Bacterial Vaginosis Drug Market Analysis – by Distribution Channel
10.1 Hospital Pharmacies
10.1.1 Overview
10.1.2 Hospital Pharmacies: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Online Pharmacies
10.2.1 Overview
10.2.2 Online Pharmacies: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Retail Pharmacies
10.3.1 Overview
10.3.2 Retail Pharmacies: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11. Bacterial Vaginosis Drug Market – Geographical Analysis
11.1 North America
11.1.1 North America Bacterial Vaginosis Drug Market Overview
11.1.2 North America: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.1 North America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Type
11.1.2.2 North America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Route of Administration
11.1.2.3 North America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Dosage Form
11.1.2.4 North America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Distribution Channel
11.1.3 North America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Country
11.1.3.1 North America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Country
11.1.3.2 United States: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.1.3.2.1 United States: Bacterial Vaginosis Drug Market Breakdown, by Type
11.1.3.2.2 United States: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.1.3.2.3 United States: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.1.3.2.4 United States: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.1.3.3 Canada: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.1.3.3.1 Canada: Bacterial Vaginosis Drug Market Breakdown, by Type
11.1.3.3.2 Canada: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.1.3.3.3 Canada: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.1.3.3.4 Canada: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.1.3.4 Mexico: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.1.3.4.1 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Type
11.1.3.4.2 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.1.3.4.3 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.1.3.4.4 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.2 Europe
11.2.1 Europe Bacterial Vaginosis Drug Market Overview
11.2.2 Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.2.2.1 Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Type
11.2.2.2 Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Route of Administration
11.2.2.3 Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Dosage Form
11.2.2.4 Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Distribution Channel
11.2.3 Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Country
11.2.3.1 Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Country
11.2.3.2 Germany: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.2.1 Germany: Bacterial Vaginosis Drug Market Breakdown, by Type
11.2.3.2.2 Germany: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.2.3.2.3 Germany: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.2.3.2.4 Germany: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.2.3.3 United Kingdom: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.3.1 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Type
11.2.3.3.2 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.2.3.3.3 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.2.3.3.4 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.2.3.4 France: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.4.1 France: Bacterial Vaginosis Drug Market Breakdown, by Type
11.2.3.4.2 France: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.2.3.4.3 France: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.2.3.4.4 France: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.2.3.5 Spain: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.5.1 Spain: Bacterial Vaginosis Drug Market Breakdown, by Type
11.2.3.5.2 Spain: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.2.3.5.3 Spain: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.2.3.5.4 Spain: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.2.3.6 Italy: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.6.1 Italy: Bacterial Vaginosis Drug Market Breakdown, by Type
11.2.3.6.2 Italy: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.2.3.6.3 Italy: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.2.3.6.4 Italy: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.2.3.7 Rest of Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.7.1 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Type
11.2.3.7.2 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.2.3.7.3 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.2.3.7.4 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.3 Asia Pacific
11.3.1 Asia Pacific Bacterial Vaginosis Drug Market Overview
11.3.2 Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.3.2.1 Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Type
11.3.2.2 Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Route of Administration
11.3.2.3 Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Dosage Form
11.3.2.4 Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Distribution Channel
11.3.3 Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Country
11.3.3.1 Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Country
11.3.3.2 China: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.2.1 China: Bacterial Vaginosis Drug Market Breakdown, by Type
11.3.3.2.2 China: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.3.3.2.3 China: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.3.3.2.4 China: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.3.3.3 Japan: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.3.1 Japan: Bacterial Vaginosis Drug Market Breakdown, by Type
11.3.3.3.2 Japan: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.3.3.3.3 Japan: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.3.3.3.4 Japan: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.3.3.4 India: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.4.1 India: Bacterial Vaginosis Drug Market Breakdown, by Type
11.3.3.4.2 India: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.3.3.4.3 India: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.3.3.4.4 India: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.3.3.5 Australia: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.5.1 Australia: Bacterial Vaginosis Drug Market Breakdown, by Type
11.3.3.5.2 Australia: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.3.3.5.3 Australia: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.3.3.5.4 Australia: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.3.3.6 South Korea: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.6.1 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Type
11.3.3.6.2 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.3.3.6.3 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.3.3.6.4 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.3.3.7 Rest of APAC: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.7.1 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Type
11.3.3.7.2 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.3.3.7.3 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.3.3.7.4 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.4 Middle East and Africa
11.4.1 Middle East and Africa Bacterial Vaginosis Drug Market Overview
11.4.2 Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.4.2.1 Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Type
11.4.2.2 Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Route of Administration
11.4.2.3 Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Dosage Form
11.4.2.4 Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Distribution Channel
11.4.3 Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Country
11.4.3.1 Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Country
11.4.3.2 Saudi Arabia: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.2.1 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Type
11.4.3.2.2 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.4.3.2.3 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.4.3.2.4 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.4.3.3 South Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.3.1 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Type
11.4.3.3.2 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.4.3.3.3 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.4.3.3.4 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.4.3.4 United Arab Emirates: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.4.1 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Type
11.4.3.4.2 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.4.3.4.3 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.4.3.4.4 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.4.3.5 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.5.1 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Type
11.4.3.5.2 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.4.3.5.3 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.4.3.5.4 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.5 South and Central America
11.5.1 South and Central America Bacterial Vaginosis Drug Market Overview
11.5.2 South and Central America: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.5.2.1 South and Central America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Type
11.5.2.2 South and Central America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Route of Administration
11.5.2.3 South and Central America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Dosage Form
11.5.2.4 South and Central America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Distribution Channel
11.5.3 South and Central America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Country
11.5.3.1 South and Central America: Bacterial Vaginosis Drug Market – Revenue and Forecast Analysis – by Country
11.5.3.2 Brazil: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.2.1 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Type
11.5.3.2.2 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.5.3.2.3 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.5.3.2.4 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.5.3.3 Argentina: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.3.1 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Type
11.5.3.3.2 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.5.3.3.3 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.5.3.3.4 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.5.3.4 Rest of South and Central America: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.4.1 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Type
11.5.3.4.2 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
11.5.3.4.3 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
11.5.3.4.4 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Bacterial Vaginosis Drug Market
12.3 Organic Growth Strategies
12.3.1 Overview
12.4 Inorganic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Bayer AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Pfizer Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Sanofi SA
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Starpharma Holdings Limited
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Viatris Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Glenmark Pharmaceuticals Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Lupin Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Sun Pharmaceutical Industries Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Organon & Co
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Duchesnay Inc., Canada
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms for Bacterial Vaginosis Drug Market
LIST OF TABLES
Table 1. Bacterial Vaginosis Drug Market Segmentation
Table 2. Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 3. Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million) – by Route of Administration
Table 4. Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million) – by Dosage Form
Table 5. Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 6. North America: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 7. North America: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 8. North America: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 9. North America: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 10. North America: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 11. United States: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 12. United States: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 13. United States: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 14. United States: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 15. Canada: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 16. Canada: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 17. Canada: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 18. Canada: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 19. Mexico: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 20. Mexico: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 21. Mexico: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 22. Mexico: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 23. Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 24. Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 25. Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 26. Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 27. Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 28. Germany: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 29. Germany: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 30. Germany: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 31. Germany: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 32. United Kingdom: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 33. United Kingdom: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 34. United Kingdom: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 35. United Kingdom: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 36. France: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 37. France: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 38. France: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 39. France: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 40. Spain: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 41. Spain: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 42. Spain: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 43. Spain: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 44. Italy: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 45. Italy: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 46. Italy: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 47. Italy: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 48. Rest of Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 49. Rest of Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 50. Rest of Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 51. Rest of Europe: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 52. Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 53. Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 54. Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 55. Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 56. Asia Pacific: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 57. China: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 58. China: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 59. China: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 60. China: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 61. Japan: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 62. Japan: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 63. Japan: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 64. Japan: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 65. India: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 66. India: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 67. India: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 68. India: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 69. Australia: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 70. Australia: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 71. Australia: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 72. Australia: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 73. South Korea: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 74. South Korea: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 75. South Korea: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 76. South Korea: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 77. Rest of APAC: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 78. Rest of APAC: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 79. Rest of APAC: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 80. Rest of APAC: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 81. Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 82. Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 83. Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form
Table 84. Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 85. Middle East and Africa: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 86. Saudi Arabia: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 87. Saudi Arabia: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Route of Administration
Table 88. Saudi Arabia: Bacterial Vaginosis Drug Market – Revenue and Forecast to 2031(US$ Million) – by Dosage Form

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us